Introduction: Multiple sclerosis (MS) treatment has changed considerably in recent years
thanks to the introduction of ever-more-powerful drugs. Unfortunately, the higher efficacies of …

Introduction Multiple sclerosis (MS) is a neurodegenerative disease characterized by
progressive deterioration of cognitive and physical functioning, reducing activities of daily …

Background Multiple sclerosis (MS) patients are faced with complex risk-benefit profiles of
disease-modifying drugs (DMDs) when making treatment decisions. For effective shared …

Shared decision-making (SDM) between the patient and their healthcare provider (HCP) in
developing treatment plans is increasingly recognized as central to improving treatment …

Introduction Initiating disease-modifying treatments (DMTs) in multiple sclerosis (MS) is a
major decision for people with (pw) MS but little is known about how the decision is …

Introduction The introduction of several new disease-modifying therapies (DMTs) to the field
of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a …

Multiple sclerosis (MS) is a chronic and progressive neurological disorder impacting
physical, cognitive, and psychosocial health. The disease course, severity, and presence of …

Patients and health authorities increasingly claim active roles in health care decision making
processes. As immune therapies in MS are partially effective MS is a prototypic condition for …

For patients with multiple sclerosis (MS) involvement in treatment decisions becomes ever
more imperative. Recently new therapeutic options have become available for the treatment …

Objective: The aim of this study is to estimate the willingness of multiple sclerosis (MS)
patients to accept life-threatening adverse event risks in exchange for improvements in their …